Valor pronóstico de los marcadores moleculares en el carcinoma broncogénico / Prognostic value study of lung cancer molecular markers

Fundamentos y objetivo: Estudio pronóstico de marcadores moleculares implicados en la carcinogénesis del carcinoma broncogénico (CB), en pacientes con CB no microcítico (CBNM) resecado en estadios iniciales. Material y método: Estudio observacional y de cohorte de pacientes con CBNM en estadios iniciales intervenidos en el Hospital 12 de Octubre de Madrid entre el 1 de octubre de 1993 y el 30 de septiembre de 1997. Se estudiaron 32 proteínas con un análisis inmunohistoquímico semicuantitativo. Se realizó un análisis de la expresión de cada proteína en relación con la supervivencia a 5 años mediante las pruebas de Wilcoxon-Gehan y log rank, aceptando como significativo un valor de p<0,05.ResultadosEl número final de pacientes incluidos fue de 146. La supervivencia a 5 años fue del 37,7%. De las 32 proteínas, hemos encontrado tres con significado pronóstico a 5 años: la expresión de RB, asociada a mejor pronóstico (p=0,01), y la expresión de p27 (p=0,03) y Ki67 (p=0,04), asociadas a peor pronóstico. En el análisis según histología no hay ninguna proteína con valor pronóstico en CB epidermoide, mientras que hay cinco en adenocarcinomas. Conclusiones: En esta serie de CBNM resecado hay 3 marcadores moleculares con valor pronóstico a largo plazo en la población general y cinco en adenocarcinomas. Probablemente, en el futuro los factores moleculares se unan a los de extensión anatómica y clínicos en una clasificación pronóstica multidimensional en CB (AU)

Background and objective: The aim of this study was to determine the prognostic value of molecular markers (proteins) of different paths of lung cancer development in patients with non small cell lung carcinoma (NSCLC) in initial stages. Material and method: Observational, cohort study in patients with NSCLC that was initially treated surgically in our hospital between October 1993 and September 1997. Thirty-two proteins were selected. The study consisted of the elaboration of tissue arrays with samples from resected tumour, using a semiquantitative immunohistochemical study. A prognosis analysis was done with the expression of each protein and calculation of the overall 5-year survival rate. The Wilcoxon-Gehan and Log-Rank tests were used for statistical comparisons, with p<.05 being considered to indicate a significant result. Results: One hundred and forty six patients were studied. The overall 5-year survival rate was 37.7%. From 32 proteins studied, three were statistically associated with overall 5-year survival rate. RB protein expression in resected NSCLC was a positive prognostic factor (P=.01). P27 (P=.03) and Ki67 (P=.04) expression in resected NSCLC were negative prognostic factors. There was no protein with prognostic value in epidermoid tumours. Conclusions: We found three proteins with long-term prognostic value in the long-term in the general population and five adenocarcinoma prognostic proteins in our study of resected non-small cell lung cancer (NSCLC). In the future, genetic-molecular factors should be included along with anatomical (TNM staging) and clinical factors in a multidimensional lung cancer staging (AU)

Linfoma de Burkitt no endémico de origen gástrico / Nonendemic Burkitt`s lymphoma of gastric origin

Describimos clínicopatológicamente un caso de linfoma de Burkitt no endémico, excepcional por la edad de aparición (21 años) y por su origen anatómico (el estómago). Presentamos y discutimos los resultados de su estudio inmunohistoquímico y el estadiaje, tumoral, que consideramos una importante aportación a la. literatura, ya que hasta la fecha no existen estudios estadísticamente concluyentes que definan fenotípicamente el linfoma de Burkitt no endémico y que correlacionen su origen anatómico, su estadiaje -tumoral y su pronóstico (AU)

Macaque lymphocytes transduced by a constitutively expressed interferon beta gene display an enhanced resistance to SIVmac251 infection.

We are developing a method of gene therapy of HIV infection based on the low constitutive expression of an interferon beta (IFN-beta) gene in HIV target cells. Herein we report the first step in the development of a relevant animal model, provided by the macaque (Macaca fascicularis) infected with a pathogenic SIVmac251 isolate. To avoid the possibility of in vivo rejection of macaque lymphocytes expressing Hu IFN-beta, we have PCR-amplified and sequenced the Ma IFN-beta-coding sequence, and placed it under the control of a PstI-NruI 0.6-kb fragment of the murine H-2Kb gene promoter in the MFG-K(b)MaIFNbeta retroviral vector. Lymphocytic CEMX174 cells, transduced by coculture on packaging cells with this construct, harbored a mean of 0.07 to 1.2 copies of the IFN-beta transgene per cell, and were characterized by an IFN production ranging from 75 to 750 units per 5 x 10(5) cells per 3 days. The IFN-beta-transduced populations displayed an enhanced resistance against the pathogenic SIVmac251 isolate. Control experiments showed that the enhanced resistance could not be ascribed to the Ma IFN-beta released during the 3 days of coculture by the packaging cells, or to the mere transduction with a retroviral vector. Macaque lymphocytes transduced by the MFG-K(b)MaIFNbeta retroviral vector by coculture on packaging cells, acquired a mean number of IFN-beta transgene copies per cell ranging from 0.03 to 0.1. Such transduction led to the release of IFN-beta into the culture medium, ranging from 10 to 20 units per 5 x 10(5) cells per 3 days. This increased the anti-SIV resistance of the lymphocytes, as demonstrated by a decreased p27 antigen release into the culture medium, without affecting lymphocyte proliferation.

The post-transcriptional regulator Rex of the human T-cell leukemia virus type I is present as nucleolar speckles in infected cells.

The rex-encoded protein (Rex) of human T-cell leukemia virus type I (HTLV-I) is responsible for the cytoplasmic accumulation of incompletely spliced mRNAs that encode the virion structural proteins. Rex is known to be located predominantly in the cell nucleoli in transient transfections or in the isolated nuclei of HTLV-I-infected cells. However, precise location of Rex under physiological conditions has not been determined unequivocally. Here we report that Rex is primarily located as intranucleolar speckles in HTLV-I-infected cells, except for a few nucleoplasmic speckles. This is in contrast to the more diffuse nucleolar distribution of the rev-encoded protein (Rev) of human immunodeficiency virus type 1 (HIV-1), the functional homologue to Rex, in HIV-1-infected cells. Accumulation of Rev is associated with disruption of nucleolar structure and cell death, whereas Rex does not have these effects. The difference in distribution of Rex and Rev within the nucleoli may reflect the difference of toxicity toward the host cells. Involvement of the nucleolus in processing of certain mRNAs is also discussed.

Effector domains of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex are functionally interchangeable and share an essential peptide motif.

The human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex transactivators are posttranscriptional regulatory proteins that promote retroviral gene expression by interacting with specific viral mRNAs. Rev and Rex have markedly dissimilar amino acid sequences and RNA target specificities but are thought to act through the same cellular pathway. In this report, we demonstrate that short peptide domains which are required for effector activity in Rev and Rex are functionally interchangeable. Activity of these effector domains depends upon a previously unrecognized tetrapeptide motif that is present in both Rev and Rex and also in analogous proteins from other complex retroviruses. The conserved effector motif may mediate essential interactions of Rev, Rex, and other transactivators of this type with a common cellular cofactor.

The nucleolar localisation signal of the HTLV-I protein p27rex is important for stabilisation of IL-2 receptor alpha subunit mRNA by p27rex.

In this study we investigated the mechanism of stabilisation of IL-2 receptor alpha subunit mRNA by the HTLV-I protein p27rex. We tested the role of the nucleolar targetting signal in rex by introducing mutations. Three deletion mutants could not express rex protein in the nucleolus and although protein was still expressed in the nucleoplasm none of the mutants could stabilise IL-2R alpha mRNA. A substitution mutant could be expressed in the nucleolus and could also stabilise IL-2R alpha mRNA. The data show that the nucleolar targetting signal is crucial for stabilisation of IL-2R alpha mRNA by rex and raise the possibility that transport of mRNA from nucleus to cytoplasm can involve the nucleolus.

Transdominant repressors for human T-cell leukemia virus type I rex and human immunodeficiency virus type 1 rev function.

Human T-cell leukemia virus type I (HTLV-I) encodes a 27-kDa trans-acting gene product (Rex) which is involved in the regulated expression of transcripts coding for the viral structural proteins. We used oligonucleotide-directed mutagenesis to generate a series of mutant HTLV-I rex genes. Transient expression experiments demonstrated that 3 of 28 mutant proteins are functionally inactive on the homologous HTLV-I rex response element, whereas an additional 2 mutant proteins are functionally inactive on the heterologous human immunodeficiency virus type 1 rev response element. One of these mutants is able to suppress the function of the wild-type HTLV-I Rex protein in trans on the homologous rex response element sequence. Furthermore, all of these mutants are able to inhibit Rex function on the heterologous rev response element sequence. Intriguingly, only three of these mutants are able to inhibit the human immunodeficiency virus type 1 Rev protein in a dominant-negative manner.